Leen Kawas on Guiding the Next Wave of Biotech Founders
- bobby
- 0
- Posted on
The biotechnology industry thrives on discovery, but discovery alone does not guarantee success. For Leen Kawas, co-founder and managing general partner of Propel Bio Partners, the future of biotech depends on cultivating founders who can navigate both science and business with resilience. Having built her own career as a scientist, inventor, and entrepreneur, Kawas now focuses on guiding the next generation of leaders so that promising ideas can translate into therapies that change lives.
Kawas’ perspective is shaped by her own path. As the co-founder and former CEO of Athira Pharma, she advanced late-stage clinical programs and took the company public in 2020, raising more than $400 million. The achievement placed her among a small number of women founders in the United States who have taken companies public. That experience, marked by both breakthroughs and challenges, informs her work today as she mentors new entrepreneurs. She understands firsthand the pressures biotech founders face and the skills required to sustain momentum.
At Propel Bio Partners, Kawas emphasizes that supporting founders is not simply a matter of providing capital. Investment, in her view, must be paired with strategic guidance, operational support, and encouragement. Many founders enter the industry with deep scientific expertise but little exposure to fundraising, regulatory navigation, or the demands of building teams. Kawas believes that bridging this gap is crucial if innovation is to reach patients. Propel’s model is designed to equip founders with the tools to handle these realities without losing sight of their scientific mission.
One lesson she stresses is the importance of resilience. Biotech ventures are notoriously high-risk, and setbacks are inevitable. Leen Kawas highlights that founders who learn to adapt to failure without abandoning their vision are better positioned to succeed. She shares with new leaders the value of persistence, reminding them that the ability to recalibrate quickly can determine whether an idea fades or eventually finds its place in the market.
She also underscores the need for clear communication. Scientists accustomed to technical language often struggle to explain their work to investors, policymakers, or the public. Kawas encourages founders to develop the skill of translating complex science into narratives that resonate with diverse audiences. This ability not only attracts funding but also builds trust among stakeholders who must support a company’s growth. For her, effective communication is as essential as strong data.
Diversity and inclusion are other themes Kawas weaves into her guidance. She points out that biotech innovation benefits when leadership teams reflect a range of backgrounds and perspectives. Founders who embrace diversity in hiring and collaboration can access broader networks and generate more creative solutions. Kawas, herself an immigrant who began her professional journey in Jordan, brings personal conviction to this message. As explored in this interview with Principal Post, she argues that global challenges require leaders who think beyond narrow boundaries.
In addition, Kawas draws attention to the balance between ambition and discipline. Founders often dream of revolutionizing medicine, but those dreams must be paired with rigorous planning and execution. She advises entrepreneurs to pursue bold goals while maintaining realistic milestones. This balance, she explains, is what keeps teams motivated and investors confident. Without discipline, ambition risks becoming unsustainable.
Her role at Propel Bio Partners also allows her to foster collaboration across the biotech ecosystem. She encourages founders to see themselves not as competitors in isolation but as part of a broader community working toward shared goals. Partnerships with academic institutions, pharmaceutical companies, and patient advocacy groups expand the impact of individual discoveries. Kawas believes that founders who embrace collaboration accelerate progress for the entire sector.
The deeper lesson she offers is that building a biotech company is as much about people as it is about science. Founders must cultivate trust, inspire teams, and connect their work to patient needs. Leen Kawas guides them to see leadership not as authority but as service, with the ultimate purpose of translating innovation into improved outcomes for patients around the world.
For Leen Kawas, guiding the next wave of biotech founders is both professional mission and personal conviction. Her journey from scientist to entrepreneur to investor gives her a unique vantage point. She knows the difficulties of the path, yet she also knows its potential to transform lives. By investing not only in ideas but in the leaders behind them, she ensures that the future of biotech will be shaped by founders who are prepared, resilient, and visionary.
For more on Leen Kawas, check out this interview on billionsuccess.com.